证券代码：688506 证券简称：百利天恒 公告编号：2025-037 四川百利天恒药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 本次股东大会由公司董事会召集，会议由公司半数以上的董事共同推举的董 事张苏娅女士主持。会议采用现场投票和网络投票相结合的表决方式。本次股东 大会的召集和召开程序、出席会议人员的资格和召集人资格、会议的表决程序和 表决结果均符合《公司法》及《公司章程》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 30 日 （二） 股东大会召开的地点：成都市高新区高新国际广场 B 座 10 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 241 | | --- | --- | | 普通股股东人数 | 241 | | 2、出席会议的股东所持 ...

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：（86-28）6739-8000 传真：（86-28）6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于四川百利天恒药业股份有限公司 2024 年年度股东大会的法律意见书 致：四川百利天恒药业股份有限公司 2. 根据《股东大会通知》，本次股东大会采取现场投票与网络投票相结合的 方式召开。 本次股东大会现场会议于 2025 年 4 月 30 日 14:30 时在成都市高新区高新国 际广场 B 座 10 楼会议室召开。董事长因其他工作安排未能现场出席本次股东大 会，根据《公司法》《股东会规则》及《公司章程》的规定，由贵公司半数以 上的董事共同推举的董事张苏娅女士主持。 北京君合（成都）律师事务所（以下简称"本所"）受四川百利天恒药业 股份有限公司（以下简称"贵公司"）的委托，根据《中华人民共和国公司法》 （以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）等中华人民共和国现行有效的有关法律、行政法规、部门规章、规范性 文件（以下合称"法律法规"，仅为本法律意见书法律 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-036 四川百利天恒药业股份有限公司 关于参加 2024 年度科创板创新药行业集体业绩说明会暨 召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 30 日(星期三)至 5 月 7 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过四川百利天恒药业股份 有限公司（以下简称"公司"）邮箱 ir@baili-pharm.com 进行提问，公司将在说 明会上对投资者普遍关注的问题进行回答。 （一） 会议召开时间：2025 年 5 月 8 日（星期四）15:00-17:00 公司已于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 公司 2024 年年度报告，并于 2025 年 4 月 30 日披露 2025 年第一季度报告，为便 于广大投资者更全面深入地了解公司 2024 年度及 2025 年第一季度的经营成 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥67,439,982.29, a decrease of 98.77% compared to ¥5,462,123,134.28 in the same period last year[4] - The net profit attributable to shareholders was -¥531,435,850.51, representing a decline of 110.62% from ¥5,005,155,365.45 year-on-year[4] - Basic and diluted earnings per share were both -¥1.33, down 110.66% from ¥12.48 in the previous year[4] - The company reported a significant decrease in net profit due to a sharp decline in operating revenue and an increase in R&D expenses[7] - The net loss for Q1 2025 was CNY 531,435,850.51, a stark contrast to a net profit of CNY 5,005,155,365.45 in Q1 2024[19] - The company reported a total comprehensive loss of CNY -530,297,772.33 in Q1 2025, compared to a comprehensive income of CNY 5,003,708,460.37 in Q1 2024[20] Research and Development - Research and development expenses totaled ¥494,913,002.18, an increase of 98.95% compared to ¥248,767,838.91 in the previous year[5] - The ratio of R&D expenses to operating revenue surged to 733.86%, up by 729.31 percentage points from 4.55% in the previous year[5] - The company aims to accelerate the R&D progress of its product pipeline to maintain its competitive advantage and expedite product launches[7] - The company is focusing on expanding its R&D efforts, as indicated by the substantial increase in R&D expenses[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥489,838,426.73, a decline of 109.11% from ¥5,378,961,733.25 in the same period last year[4] - Total cash inflow from operating activities in Q1 2025 was 183,689,270.20, down from 5,829,179,801.63 in Q1 2024[22] - Cash outflow from operating activities increased to 673,527,696.93 in Q1 2025, compared to 450,218,068.38 in Q1 2024[23] - Cash flow from investing activities showed a net inflow of 209,854,280.88 in Q1 2025, contrasting with a net outflow of -9,184,007.40 in Q1 2024[23] - Cash inflow from financing activities rose to 1,010,000,000.00 in Q1 2025, compared to 100,000,000.00 in Q1 2024[23] - The net cash flow from financing activities was 738,974,554.43 in Q1 2025, up from 54,781,142.67 in Q1 2024[23] - The ending cash and cash equivalents balance for Q1 2025 was 3,661,101,912.06, compared to 5,811,813,000.70 in Q1 2024[24] - The company received 10,042,314.81 in tax refunds in Q1 2025, an increase from 3,423,343.57 in Q1 2024[22] - The company paid 201,852,112.05 in employee compensation in Q1 2025, compared to 113,533,587.71 in Q1 2024[23] - The cash outflow for other operating activities was 386,816,933.38 in Q1 2025, compared to 279,735,605.89 in Q1 2024[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,439,191,804.86, an increase of 4.23% from ¥7,137,357,660.07 at the end of the previous year[5] - Total liabilities increased to CNY 4,067,763,407.83 in Q1 2025 from CNY 3,251,432,880.03 in Q1 2024, marking an increase of approximately 25%[15] - The company's total equity decreased to CNY 3,371,428,397.03 in Q1 2025 from CNY 3,885,924,780.04 in Q1 2024, reflecting a decline of about 13%[15] - Shareholders' equity attributable to shareholders decreased by 13.24% to ¥3,371,428,397.03 from ¥3,885,924,780.04 at the end of the previous year[5] - The total current assets as of March 31, 2025, amounted to ¥6,568,169,083.49, an increase from ¥6,307,204,588.11 as of December 31, 2024, representing a growth of approximately 4.14%[12] - Cash and cash equivalents increased to ¥3,667,937,163.82 from ¥3,220,120,969.20, reflecting a rise of about 13.9%[12] - Inventory levels rose to ¥192,941,670.97 from ¥162,191,590.25, indicating an increase of approximately 18.98%[13] - The company's long-term assets totaled ¥871,022,721.37, up from ¥830,153,071.96, which is an increase of about 4.2%[13] - Accounts receivable decreased to ¥80,167,866.70 from ¥106,715,664.97, showing a decline of approximately 25%[13] - The company reported a significant increase in prepayments, which rose to ¥97,392,571.25 from ¥81,590,484.92, reflecting a growth of about 19.4%[13] Shareholder Information - There were no changes in the top 10 shareholders or their shareholding status due to margin trading activities[11] - The company has not identified any related party transactions among its major shareholders[11] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[12]

Group 1 - The company's operating revenue for the first quarter of 2025 is 67.44 million, representing a year-on-year decline of 98.77% [1] - The company reported a net loss of 531 million, compared to a net profit of 5.005 billion in the same period last year [1]

Group 1 - The State Council Information Office will hold a press conference on April 28 to discuss policies related to stabilizing employment and the economy, promoting high-quality development [1] - The National Development and Reform Commission, Ministry of Human Resources and Social Security, Ministry of Commerce, and the People's Bank of China will present relevant measures and answer questions [1] Group 2 - The China Council for the Promotion of International Trade will hold a press conference on April 28 to release the global trade friction index for February 2025 and other trade-related data [3] - The press conference will also cover the latest preparations for the third Chain Expo and new policies to support foreign trade [3] Group 3 - The China Meteorological Administration will hold a press conference on April 28 to discuss the national weather and climate characteristics for April, as well as predictions for May [4] Group 4 - The first "Beijing Xiangshan Forum" will take place from April 28 to 30, focusing on global security challenges and opportunities, with participation from over 200 defense officials and experts from more than 30 countries [5] Group 5 - On April 28, a total of 17 companies will have their restricted shares released, amounting to 1.727 billion shares with a total market value of 24.677 billion yuan [6] - Companies with the highest share unlock volumes include China Resources Materials, Chengda Bio, and Wangbian Electric [6] Group 6 - 19 companies announced stock repurchase progress on April 28, with 18 companies disclosing new repurchase plans [7] - The highest repurchase amounts were reported by Tianyuan Environmental Protection, Jinli Permanent Magnet, and Zhenhua Heavy Industry [7] Group 7 - A total of 176 billion yuan in 7-day reverse repos will mature today, with an operation rate of 1.5% [8]

证券代码：688506 证券简称：百利天恒 公告编号：2025-035 四川百利天恒药业股份有限公司 自愿披露关于 BL-B01D1（EGFR×HER3 双抗 ADC）联合用 药治疗复发或转移性宫颈癌和晚期或复发性子宫内膜癌获得 受理号：CXSL2500114、CXSL2500119 通知书编号：2025LP01174、2025LP01175 申请事项：境内生产药品注册临床试验 申请人：成都百利多特生物药业有限责任公司；四川百利药业有限责任公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，注射用 BL-B01D1 临床试验符合药品注册的有关要求，同意本品开展联合帕博利珠单抗 双药不联合或联合贝伐珠单抗和/或化疗治疗复发或转移性宫颈癌、联合帕博利珠 单抗双药不联合或联合化疗治疗晚期或复发性子宫内膜癌的临床试验。 二、药品的其他情况 2 个 II 期药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局(NMPA) ...

中信证券股份有限公司 关于四川百利天恒药业股份有限公司 （四）现场检查时间 2024 年度持续督导工作现场检查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为四川百 利天恒药业股份有限公司（以下简称"百利天恒""公司"或"上市公司"）2025 年度向特定对象发行 A 股股票的保荐人，于 2025 年 3 月 27 日与公司签订保荐 协议，自保荐协议生效之日起，承接原保荐人国投证券股份有限公司尚未完成的 首次公开发行股票并在科创板上市的持续督导工作。根据《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》等有关法律、法规的规定，中信证券 股份有限公司对 2024 年 1 月 1 日至 2024 年 12 月 31 日（以下简称"本持续督导 期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 杨沁、陈溦 （三）现场检查人员 杨沁、陈溦、周增骏、冯暄 2025 年 3 月 17 日至 2025 年 4 月 23 日 （五）现场检查内容 现场检查人员对本持续督导期内上市公司的公司治理和内 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed A Fund, which has shown significant returns in recent months and has a strong portfolio in the healthcare sector [1][3]. - As of April 24, 2025, the fund's latest net value is 1.5450 yuan, reflecting a growth of 1.25% [1]. - The fund has achieved a return of 18.21% over the past month, ranking 2 out of 8 in its category, and a return of 30.60% over the past three months, ranking 1 out of 8 [1]. - Year-to-date, the fund has returned 28.32%, also ranking 1 out of 8 in its category [1]. Group 2 - The top ten stock holdings of the fund account for a total of 64.17%, with significant positions in companies such as Heng Rui Pharmaceutical (10.23%), Kelun Pharmaceutical (9.09%), and Bai Li Tianheng (8.94%) [1]. - The fund was established on June 18, 2015, and as of March 31, 2025, it has a total asset size of 4.408 billion yuan [1]. - The fund manager, Zhang Wei, has a strong background in biomedical studies and has held various positions in the pharmaceutical research field prior to managing this fund [2].

汇添富健康生活一年持有A业绩表现较为突出。 2025年以来的震荡市场中，沪深300指数下跌3.76%，汇添富健康生活一年持有A仍保持36.03%的正收益，跑赢 业绩比较基准超过30个百分点，同类排名34/4575。 重仓股科伦博泰生物、百利天恒年内股价涨幅超四成 汇添富健康生活一年持有基金经理为张韡。公开资料显示，张韡曾任东方证券医药助理研究员，汇添富基金医 药研究员、高级医药研究员及医药行业研究组组长。 截至2025年4月23日数据（下同），该基金近一年收益率达29.23%，成立以来回报率达到16.67%，大幅跑赢业 绩比较基准及同类平均。 基金经理张韡在行业分化中抓住结构性机会，成为近年来健康主题基金的领跑者。2025年以来，基金净值累计 上涨36.03%，同类排名34/4575。 业绩领跑：年内回报达36.03% 汇添富健康生活一年持有A成立于2021年3月，基金采用自下而上的投资方法，以深入的基本面分析为立足点， 精选健康生活主题中的优质上市公司，在科学严格管理风险的前提下，谋求基金资产的中长期稳健增值。 基金业绩比较基准为中证医药卫生指数收益率*50%+中证消费服务领先指数收益率*20%+中债综合指 ...